JoanneMortimerMD

Breast Cancer, Hematologic Oncology

Vice Chair and Professor, Department of Medical Oncology & Therapeutics Research; Director, Women's Cancer Programs, Co-director, Breast Cancer Program at City of Hope

Join to view full profile

Dr. Mortimer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mortimer's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-408-3911

Summary

I am a board certified medical oncologist with specialization in breast and women's cancers. I have been part of City of Hope team since 2007 and am currently the vice chair and professor of the Department of Medical Oncology and Therapeutic Research and co-director of the Breast Cancer Program.

I love working with women; they’re amazing people. They get a diagnosis that is, at times, potentially fatal, and manage to get through it while still taking care of their families and kids, coming out the other side as stronger people.

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1980 - 1982
Cleveland Clinic FoundationResidency, Internal Medicine, 1977 - 1980
Loyola University Chicago Stritch School of MedicineClass of 1977

Certifications & Licensure

CA State Medical License 2004 - 2026
VA State Medical License 2002 - 2006
OH State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2011 Apr 20
Active, not recruiting
Phase 2
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid Start of enrollment: 2012 Sep 14
Terminated
Not Applicable
S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Start of enrollment: 2014 May 01
Terminated
Phase 3
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer Start of enrollment: 2015 Jan 07
Active, not recruiting
Not Applicable
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer Start of enrollment: 2017 Jul 21
Active, not recruiting
Systematic Light Exposure for Fatigue in Breast Cancer Patients Start of enrollment: 2018 Jan 25
Completed
Not Applicable
Roles: Contact, Principal Investigator
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis Start of enrollment: 2022 Dec 21
Recruiting
Phase 4
Roles: Principal Investigator, Contact
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Start of enrollment: 2021 Feb 02
Active, not recruiting
Phase 1
Roles: Contact
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial Start of enrollment: 2024 Aug 28
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

219 citations
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression
Debasish Tripathy, Dennis J. Slamon, Melody A. Cobleigh, Andrew Arnold, Mansoor N. Saleh
Journal of Clinical Oncology. 2004-03-15
382 citations
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
William J Gradishar, Benjamin O Anderson, Jame Abraham, Rebecca Aft, Doreen Agnese
Journal of the National Comprehensive Cancer Network. 2020-04-01
51 citations
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients
Hei Jason Chan, Haiqing Li, Zheng Liu, Yate-Ching Yuan, Joanne E. Mortimer
Oncotarget. 2015-06-30

Journal Articles

ERα-Mediated Cell Cycle Progression Is an Important Requisite for CDK4/6 Inhibitor Response in HR+ Breast Cancer
Joanne Mortimer, Laura Kruper, Raju Pillai, George Somlo, Yuan Yuan, Oncotarget

Press Mentions

Why Black Women Are More Likely to Die from Breast CancerJune 10th, 2021
Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
High Recurrence Score Linked with Chemotherapy Success in Breast CancerOctober 8th, 2019
Join now to see all